In the last trading session, 1.21 million shares of the C4 Therapeutics Inc. (NASDAQ:CCCC) were traded. Most recently the company’s share price was $5.54, and it changed around $0.17 or 3.17% from the last close, which brings the market valuation of the company to $254.73M. CCCC currently trades at a discount to its 52-week high of $51.21, offering almost -824.37% off that amount. The share price’s 52-week low was $4.84, which indicates that the current value has risen by an impressive 12.64% since then. We note from C4 Therapeutics Inc.’s average daily trading volume that its 3-month average coming to 1.10 million.
C4 Therapeutics Inc. stock received a consensus recommendation rating of an Overweight, based on a mean score of 2.20. If we narrow it down even further, the data shows that 1 out of 12 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 3 recommended CCCC as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. C4 Therapeutics Inc. is expected to report earnings per share of -$0.69 for the current quarter.
C4 Therapeutics Inc. (NASDAQ:CCCC) trade information
Instantly CCCC has showed a green trend with a performance of 3.17% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 5.82 on Tuesday, 06/21/22 increased the stock’s daily price by 4.81%. The company’s shares are currently down -82.80% year-to-date, but still up 2.59% over the last five days. On the other hand, C4 Therapeutics Inc. (NASDAQ:CCCC) is -16.19% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $25.67, which translates to bulls needing to increase their stock price by 78.42% from its current value. Analyst projections state that CCCC is forecast to be at a low of $10.00 and a high of $84.00. In order for the stock price to hit the forecast high, the stock would need to plunge -1416.25% from its current level, while the stock would need to crash -80.51% from its current level to reach the projected low.
C4 Therapeutics Inc. (CCCC) estimates and forecasts
C4 Therapeutics Inc. share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -82.38 percent over the past six months and at a -56.59% annual growth rate that is well below the industry average of 0.60%. Moreover, analysts have decided to roll up on their fiscal year 2022 revenue estimates. The rating firms predict that it will loss -35.30% in revenue this quarter, and will report a decrease of -45.10% in the next quarter. The year-over-year growth rate is expected to be -28.70%, down from the previous year.
Consensus estimates provided by 8 financial analysts predict the company will bring in an average of $7.64 million in revenue for the current quarter. 7 analysts expect C4 Therapeutics Inc. to make $7.86 million in revenue for the quarter ending Sep 2022. Analysts predict that the company’s current quarter sales will drop, forecast at -21.90%.
C4 Therapeutics Inc.’s next quarterly earnings report is expected to be released around March 09 and March 14.
C4 Therapeutics Inc. (NASDAQ:CCCC)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 11.27% of C4 Therapeutics Inc. shares, and 74.63% of them are in the hands of institutional investors. The stock currently has a share float of 84.11%. C4 Therapeutics Inc. stock is held by 187 institutions, with Price (T.Rowe) Associates Inc being the largest institutional investor. By Dec 30, 2021, it held 8.40% of the shares, which is about 4.08 million shares worth $131.53 million.
Blackrock Inc., with 6.46% or 3.14 million shares worth $76.18 million as of Mar 30, 2022, holds the second largest percentage of outstanding shares.
Price (T.Rowe) New Horizons Fund and Price (T.Rowe) Health Sciences Fund were the top two Mutual Funds as of Dec 30, 2021. The former held 1.45 million shares worth $46.69 million, making up 2.98% of all outstanding shares. On the other hand, Price (T.Rowe) Health Sciences Fund held roughly 1.2 million shares worth around $38.48 million, which represents about 2.46% of the total shares outstanding.